Welcome to our dedicated page for ZyVersa Therapeutics news (Ticker: ZVSA), a resource for investors and traders seeking the latest updates and insights on ZyVersa Therapeutics stock.
ZyVersa Therapeutics, Inc. (ZVSA) generates a steady flow of news related to its progress as a clinical-stage specialty biopharmaceutical company focused on renal and inflammatory diseases. Company press releases and SEC filings highlight developments around its two proprietary platforms: Cholesterol Efflux Mediator™ VAR 200 for kidney diseases and Inflammasome ASC Inhibitor IC 100 for chronic inflammatory and cardiometabolic conditions.
News coverage for ZyVersa frequently centers on clinical and preclinical milestones. For VAR 200, investors can follow announcements about the initiation and conduct of a phase 2a proof-of-concept trial in patients with diabetic kidney disease, plans for subsequent studies in focal segmental glomerulosclerosis and Alport syndrome, and use of VAR 200 under FDA-authorized Emergency Compassionate Use in a patient with ApoCII amyloidosis. Releases also discuss preclinical data showing reduced renal lipid accumulation, protection against renal injury and fibrosis, and improvement in proteinuria in multiple kidney disease models.
For IC 100, ZyVersa issues news highlighting preclinical data in cardiometabolic and neurological models, including effects on insulin resistance, vascular inflammation, and cardiac function, as well as plans for IND-enabling studies in a diet-induced obesity model and a future phase 1 trial in overweight subjects at risk for cardiometabolic conditions. The company also reports on scientific publications and review articles that, in its view, support the rationale for targeting inflammasomes and renal lipotoxicity.
Another recurring theme in ZyVersa’s news is corporate and capital markets activity. Releases describe equity purchase agreements, warrant inducement transactions, and financing arrangements intended to fund ongoing research and development, along with updates on its trading status following the delisting of its common stock from Nasdaq and quotation on the OTCQB Venture Market under the symbol ZVSA.
By monitoring this news page, readers can track ZyVersa’s reported clinical progress, preclinical findings, financing events, and regulatory and listing updates, all drawn from the company’s own press releases and related disclosures.
ZyVersa Therapeutics (Nasdaq: ZVSA) has secured a share purchase agreement with Williamsburg Venture Holdings for up to $10 million to fund clinical development of its Cholesterol Efflux Mediator™ VAR 200 for chronic kidney diseases. The 24-month agreement allows ZyVersa to sell common stock to WVH at market-discounted prices, with ZyVersa maintaining full control over timing and amount of sales.
The agreement includes a 2.5% commitment share issuance to WVH based on purchased amounts. The funding aims to support VAR 200's development in the kidney disease market, which is projected to grow from $18 billion in 2024 to $30 billion by 2034.
ZyVersa Therapeutics announces breakthrough data for their Inflammasome ASC Inhibitor IC 100 in treating Parkinson's Disease (PD). The study, published in npj Parkinson's Disease and supported by the Michael J. Fox Foundation, shows IC 100's potential to slow PD progression.
Key findings demonstrate that IC 100 effectively blocks microglial inflammasome activation and reduces neurotoxic alpha-synuclein accumulation - two major factors in PD progression. The research, conducted at the University of Miami Miller School of Medicine, reveals the first evidence linking ASC speck assembly, NLRP1 inflammasome activation, and alpha-synuclein aggregation in PD patients' neurons.
The global PD drug market, valued at $6.6 billion in 2024, is projected to reach $13.3 billion by 2034. Unlike current treatments that only address symptoms, IC 100 shows promise as a disease-modifying therapy. ZyVersa plans to begin proof-of-concept animal studies later this year.
ZyVersa Therapeutics (NASDAQ: ZVSA) has issued a shareholder letter highlighting key developments in inflammasome inhibitor research and their IC 100 program. The global anti-inflammatory biologics market, valued at $105 billion in 2024, is projected to reach $186 billion by 2034.
The company's IC 100, an Inflammasome ASC Inhibitor, is being developed for chronic inflammatory diseases, focusing initially on obesity-associated cardiometabolic conditions. Key upcoming milestones include:
- Proof-of-concept study in diet-induced obesity mouse model starting H1-2025
- IND submission planned for H2-2025
- Phase 1 clinical trial initiation in overweight subjects following IND approval
- Completion of preclinical study for Parkinson's disease treatment, funded by The Michael J. Fox Foundation
ZyVersa Therapeutics (NASDAQ: ZVSA) announces significant developments regarding their drug VAR 200 for Focal Segmental Glomerulosclerosis (FSGS). The PARASOL initiative's recent recommendations are expected to streamline FSGS drug development by accepting proteinuria reduction over 24 months as a surrogate endpoint for regulatory approval, replacing the need for long-term kidney failure outcomes.
The company plans to initiate a Phase 2a proof-of-concept trial for VAR 200 in Diabetic Kidney Disease (DKD) patients in the first half of 2025, before proceeding with FSGS trials. This strategic approach aims to gather preliminary human renal data and optimize future FSGS study protocols.
FSGS affects approximately 40,000 people in the US and currently has no approved drug therapies. The global kidney disease drug market reached $18 Billion in 2024 and is projected to reach $30 Billion by 2034. VAR 200, targeting cholesterol accumulation in kidney filtration systems, is positioned as an add-on therapy to existing treatments.
ZyVersa Therapeutics (ZVSA) reported its full year 2024 financial results and provided pipeline updates. The company plans to begin a Phase 2a clinical trial for VAR 200 in diabetic kidney disease patients in H1-2025, and expects to submit an IND for IC 100 in H2-2025.
Key financial highlights include:
- Net loss of $9.4 million for 2024, improved 90.4% from $98.3 million in 2023
- R&D expenses decreased 44.5% to $1.8 million
- G&A expenses reduced 34.4% to $7.4 million
- Raised approximately $6.6 million in 2024 and $2.0 million in Q1-2025
The company's cash position of $1.5 million as of December 31, 2024, will fund operations on a month-to-month basis, requiring additional financing to support continuing operations and meet stated milestones.
ZyVersa Therapeutics (NASDAQ: ZVSA) has highlighted new animal model data showing that inflammasome inhibition can help treat obesity-associated cardiomyopathy (OAC), a condition with less than 50% five-year survival rate. The study, published in the Journal of the American Heart Association, demonstrated that NLRP3 inflammasome inhibition produced several positive outcomes in obese mice, including:
- Reduced body weight and fasting blood glucose
- Decreased cardiac inflammation
- Prevented enlarged heart muscle and fibrosis
- Improved cardiac dysfunction
- Reduced cardiac lipid accumulation
The findings support the potential of ZyVersa's Inflammasome ASC Inhibitor IC 100 as a treatment for obesity-related cardiovascular conditions. IC 100 targets the ASC component of inflammasomes, inhibiting multiple inflammasomes (NLRP1, NLRP3, NLRC4, and AIM2) and ASC Specks that spread inflammation.
ZyVersa Therapeutics (NASDAQ: ZVSA) has highlighted new data showing how inflammasome inhibition reduces neuroinflammation and amyloid beta (Aβ) buildup in Alzheimer's disease (AD) mouse models. The research, published in Immunity journal, demonstrates that NLRP3 inhibition significantly attenuates AD pathology development.
The study reveals that initial Aβ deposition triggers NLRP3 inflammasome activation, leading to ASC specks release which enhances Aβ aggregation. This creates a cycle of inflammation and Aβ deposition in the brain. ZyVersa's Inflammasome ASC Inhibitor IC 100 shows potential as a treatment for neurodegenerative diseases by targeting ASC and inhibiting multiple inflammasome pathways.
Key findings show that NLRP3 inhibition:
- Increased degradation and elimination of Aβ in microglia through phagocytosis
- Enhanced microglial metabolic activity through increased glutamine utilization
- Improved mitochondrial function